Comments
Shares in Sun Pharmaceutical Industries slumped as much as 16 per cent, heading towards their biggest daily fall ever, after the drugmaker on Monday said it sees 2016 sales flat at best.
Analysts say results warning can cut FY16 consensus earnings estimates by 8-10 per cent as company struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.
At 9.30 am, the Sun Pharma pared its losses a bit, but still trading down 13.5 per cent or Rs 128 at Rs 820 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.